Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cariprazine - Gedeon Richter

Next Previous
X
Search
Drug Profile

Cariprazine - Gedeon Richter

Alternative Names: Cariprazine prolonged release; MP-214; REAGILA; Reagila; RGH-188; RGH-188 HCl; SYMVENU; VRAYLAR; Vraylar; WID-RGC20

Latest Information Update: 08 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gedeon Richter
  • Developer AbbVie; Gedeon Richter; Mitsubishi Tanabe Pharma Corporation; Recordati; Whanin Pharmaceutical
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; Mood stabilisers; Piperazines; Small molecules; Urea compounds
  • Mechanism of Action 5-HT2C serotonin receptor modulators; Dopamine D2 receptor partial agonists; Dopamine D3 receptor partial agonists; Histamine H1 receptor antagonists; Serotonin 1A receptor partial agonists; Serotonin 2B receptor antagonists; Serotonin 5-HT2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar depression; Bipolar disorders; Major depressive disorder; Schizophrenia
  • Phase III Pervasive child development disorders
  • No development reported Schizoaffective disorder

Most Recent Events

  • 04 Oct 2024 AbbVie completes a phase-III trial in Pervasive child development disorders (In children, In adolescents) in Puerto Rico and USA (PO) (NCT05439616)
  • 24 Sep 2024 AbbVie terminates a phase III trial in Schizophrenia in Japan and Taiwan (PO) due to business decision (NCT05368558)
  • 04 Sep 2024 AbbVie receives a positive reimbursement recommendation from Canada's Drug Agency (CDA) for Schizophrenia in adults

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top